详细内容或原文请订阅后点击阅览
Rostec 将使血浆药物产量提高 1.4 倍
位于彼尔姆的企业开设了年产能 100 吨、配备现代化设备的新血浆加工基地
来源:俄罗斯技术国有集团新闻频道A new site for processing blood plasma with a capacity of 100 tons per year, equipped with modern equipment, was opened at the enterprise in Perm
照片：“Nacimbio”
Rostec 国营公司的 Nacimbio 控股公司启动了一个新的血浆处理厂，年产能为 100 吨。该生产线配备了现代化的高科技设备，部署在彼尔姆市的 NPO Microgen 公司。 The production of drugs unique to the Russian market has been established here, including the first domestic immunoglobulin against hepatitis B. The project will increase the production of drugs from blood plasma by 40%.
新的生产基地开业，作为 NPO Microgen 生产设施大规模现代化的一部分。它的推出将增加俄罗斯患者血浆药物的可用性。 In 2027, the line will begin producing solutions for intravenous and intramuscular injections, including immunoglobulins and human albumin, which are most in demand by the healthcare system.
“The opening of a new site at the plant of our Nacimbio holding in Perm is an important strategic step of the Rostec State Corporation to reduce the dependence of Russian healthcare on imported immunobiological drugs. These medications are critical for the prevention and treatment of infections in people with impaired immune systems, blood loss, and after surgery and transplants. The commissioning of a new site will increase the total volume of plasma processing at the holding’s enterprises to 357 tons, which will provide about 40% of the Russian market’s demand for immunoglobulins and albumin. And for certain items, such as normal human immunoglobulin, it is up to 50%,” noted Deputy General Director of the Rostec State Corporation Alexander Nazarov.
At the new site, equipped with modern high-tech equipment, a full cycle of production of specific immunoglobulins, normal human immunoglobulin (in concentrations of 5% and 10%), as well as human albumin, is carried out.